J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?
2018 ◽
Vol 10
(1)
◽
pp. 106-108
◽
2013 ◽
Vol 14
(5)
◽
pp. 597-608
◽
2018 ◽
Vol 33
(4)
◽
pp. 549-550
2012 ◽
2018 ◽
Vol 13
(10)
◽
pp. S582
◽